In This Issue
Science Advisory Board
Roberto Jorge Fernandez
Honorary Professor University Maimonides Argentina Honorary Professor University of Beijing, China
Shimon Slavin, MD
Professor of Medicine Medical & Scientific Director
Carlos Lima, MD
Zannos G. Grekos, MD
Kitipan V. Arom, MD,
PhD, FACS, FACC, FACCP, FRCST
By David Granovsky, Editor
In January, reporters excitedly flooded the world media with stories on the ‘first’ embryonic stem cell clinical trial. Embryonic advocates celebrated this ridiculous assertion that a real FDA approved embryonic clinical trial would be held “early this summer.”
Every “medical” reporter in every major American city newspaper with a minimal knowledge of the limitations of embryonic stem cells for treatment and an earful of misinformation was instructed to “play it up”…and play it up they did. The only man in the world to vocally and adamantly dispute this fraud was Don Margolis; who began his condemnation of the fiasco starting the day of the announcement.
Mr Margolis was the only person to point out that Geron has a lengthy track record of such stock manipulation, “having made ten previous announcements of upcoming trials over the past five years – none of which has ever happened.”
He stated that the public (and the truth) would be better served and a very different story would be told if the misinformed reporters were to further research this ‘boywho-cried-wolf’ company. “A half-hour’s research would enlighten them that the true purpose of the announcement was to pump up the stock’s price over 35% …”
Scientists whom to date had no positive results from embryonic research for treatments and academic institutions interested in pursuing the huge funding potential were all salivating at the thought of all the grant money soon to flow into their coffers with NO chance of patients ever benefitting. All the while, Don Margolis said many times in many ways, “It will never happen!”
“The embryonic lobby will never allow any clinical trial to be held because they know that immune rejection by the patient is possible and that, based on animal research, brain tumors may be in the cards!”
“That is why we at the Repair Stem Cell Institute expect the embryonic lobby to pull its weight and stop this potential catastrophe in the making. “
“For a listed company to cynically manipulate stock prices and raise the hopes of sufferers as Geron does regularly, might be considered a bit unethical.”
In time, Mr Margolis’ statements were proven conclusively when the efforts and agendas of Geron, Wall Street and the FDA synchronized to hype the company on the false promise of an FDA approved embryonic clinical trial. Misled investors donated $43 million to Geron in a mid-February scam well documented by “TheStreet.com.” The money is in the till, and there is no need to pretend any longer that a clinical trial will be held. The eleventh known Geron fraud is complete.
Mr. Margolis concluded with uncanny accuracy: “The public, and spinal cord injury patients in particular, deserve to know the facts and to be aware that right now patients are being helped, and will be long after Geron’s trial is either yanked or fails.”
There is only one slight upside to this fiasco of criminal negligence where investors were taken advantage of, spinal cord injury patients were given false hope and the rampant misinformation of the general public continued. Embryonic stem cells used for treatment have a history of turning into tumors. To date, the only victims have been thousands of dead animals and one or two human patients with tumors. The original trial was to include 8-10 people with severe spinal cord injuries. So, with the trial on hold, that’s 8-10 people who will not have “tumors” or “death” added to their medical chart.”
What you are about to read here, you cannot read in a major city American newspaper. They are all --- every one --- a major player in the embryonic hoax, as is the president, and most of Congress. But in Europe
BRITISH EMBRYONIC LEADER TELLS IT LIKE IT AS THE EMBRYONIC HOAX STARTS TO CRUMBLE UNDER THE PRESSURE OF TRUTH
Professor Colin McGuckin is professor of regenerative medicine at Newcastle University, UK. His team was the first to characterize a harvesting and culture strategy to produce embryonic stem cells from umbilical cord blood, and the first to grow real liver tissue from umbilical cord stem cells cultured in vitro, an important step toward replacing liver transplants with new livers. In other words, a respected world-leader in his field.
Here is what the good doctor says: “The best estimates of the embryonic scientists in our own university in Newcastle is that embryonic stem cells may not be able to help people this side of 50 years. That’s my lifetime. And that’s worrying. We can’t wait that long.”
Prof. McGuckin, unlike the embryonic researchers groping for tax money for research to find cures which are so far in the future they are almost beyond imagination, has put his future where his mouth is, assuming a key role in a new European ADULT stem cell research organization, Novussanguis, three months after his courageous exposure of the embryonic truth. He is the highest ranking embryonic researcher to actually tell the truth about the overhyped promise of embryonics. From the Novussangus press release:
Cord blood and adult stem cells are very attractive for research in cell therapy and regenerative medicine because of their high differentiation and expansion potential.
Adult stem cells can be harvested from several human tissues such as brain, bone marrow, peripheral blood, liver, cornea, retina, and pancreas. It is also possible to find stem cells in umbilical cord blood. With over 130 million births per year worldwide, cord blood is a particularly important source of readily available stem cells in terms of access and supply.
Adult stem cells play a key role in research for treatment of several diseases. Today, over 80 diseases are treatable with cord blood stem cells, some linked to the blood system (e.g. leukemia) or the immune system (‘babies in a bubble’)**, but also neurological diseases (MS. CP, ALS), diseases affecting the bone marrow, nervous system, heart or metabolism such as diabetes.
**Coincidentally, the unchallenged world-leader on this "bubble" malady is our own Science Advisory Board Deputy Chairman, Prof. Shimon Slavin of Israel.
Scientists Admit Embryonic Stem Cell Research Hasn't Been Successful
London, England (LifeNews.com) -- While pro-life advocates have repeated the mantra for years that embryonic stem cell research hasn't helped a single patient while adult stem cells have already been used in humans afflicted with dozens of diseases, a leading scientist in England is beginning to admit defeat.
Lord Patel of Dunkeld, the chairman of the UK National Stem Cell Network and a chancellor at Dundee University, says embryonic stem cell research is simply not working. He conceded in an interview with The Scotsman newspaper that the controversial science may never deliver new treatments for diseases.
"In terms of embryonic stem cell therapy, there is currently no such therapy that is available in a large number of patients," he said.
Patel also admitted scientists may never be able to overcome the hurdles -- such as the development of tumors or immune syndrome rejection issues -- that plague embryonic stem cell research and make it risky in humans.
"We have to be cautious," he told the Scotsman.. "It may not deliver therapy for anything. We may find that stem therapy is quite a risky business."
"We had a lot of hype about gene therapy, and while we still use it in some cases it did not deliver the great promise we thought it would because of the side effects," he said.
Despite downplaying the prospects for success, Lord Patel told the newspaper he still thought embryonic stem cell research should move forward.
The newspaper also interviewed Dr. Willy Lensch, from the Children's Hospital in Boston, who also confirmed the possibility that the prospect of embryonic stem cell research may never play out.
"I could not guarantee to anyone that this work will actually lead to improvements in disease as a definite," he admitted.
For American bioethics watchdog Wesley Smith, the admissions aren't surprising.
"For the last ten years, 'the scientists,' in order to win the political debates over embryonic stem cell research and [human cloning] often wildly hyped the potential for cures," he said.
"In the process, they convinced Californians--now facing a $16 billion budget deficit and tens of billions in bond debt--to borrow $300 million every year to pay for human cloning and embryonic stem cell research," he explained.
"States vied with each other in an Oklahoma land race type scramble to throw money at Big Biotech. The focus of the media became obsessed with overturning President Bush's funding policy, to the point that it committed serial journalistic malpractice with biased reporting and a news blockade on non-embryonic stem cell successes," Smith added.
"Well, those cures have not even appeared as distant silhouettes on the horizon yet, and finally, a few in the media are beginning to notice," Smith concluded.
"By hyping the potential, the politicized science sector misled people to win a political debate, and in the process reduced science to just another special interest spinning and obfuscating to get a greater share of gruel in the public trough."
Embryonic Stem-Cell Firm Abandons Efforts
Investors reportedly have lost interest in an embryonic stem-cell research lab’s failed efforts to create clinical therapies, according to the company’s former chief executive.
Alan Colman, former chief executive of ES Cell International (ESI), a leading Singapore biotechnology research firm, told Science magazine that investors concluded that “the likelihood of having products in the clinic in the short term was vanishingly small.”
Dawn Vargo, associate bioethics analyst for Focus on the Family Action, said the real promise of stem-cell treatments and therapies is in adult stem cells, which do not involve the destruction of a human life.
“When prominent scientists in the field of embryonic stem-cell research say that that they need ‘success stories,’ it's pretty obvious that the real truth about embryonic stem-cell research is being revealed,” Vargo said. “The truth is that embryonic stem-cell research has yet to yield a single successful treatment for patients. Meanwhile, adult stem cells continue to provide success stories – more than 70 diseases and ailments are being treated and more than 1,500 clinical trials are using adult stem cells for treatment.”
IT MUST BE NOTED HERE THAT NO GOVERNMENT IN THE WORLD HAS BEEN MORE SUPPORTIVE OF ESC THAN THAT OF SINGAPORE.....Don Margolis
A FOURTH ARTICLE BY A RESEARCH DOCTOR WHO ADMITS THAT SHE IS ABSOLUTELY NOWHERE AND HASN'T DONE MUCH BESIDES KILL LAB ANIMALS AND KEEP THE FAITH
Stem cell therapy shows promise, problems
DANBURY -- The brave new world of stem cell therapy -- where injected cells rush to the scene of damage or disease in our bodies and provide a fix -- may still come true, but it is years away.
As researchers learn about stem cells, they are also learning about the complications of an entirely new field of study. Yet the hope persists.
"Why do we care about stem cells?" Laura Grabel asked a crowded lecture hall at Western Connecticut State University this week. "Why is this room full of people? Why does every presidential candidate feel it's necessary to give a position on stem cell research?"
Grabel -- the Fisk Professor of Natural Sciences at Wesleyan University in Middletown and one of the country's leading stem cell scientists -- spoke at WestConn about her own work trying to learn if stem cells can transform themselves into neurons, the body's nerve cells.
But she also talked of some of the pitfalls of the research, and of the broad philosophical and political issues that entangle themselves in the work.
Stem cells are the body's protean, shape-changing cells -- the fertilized cells in the human embryo that split and differentiate themselves to become all the organs and tissues of the body.
The great hope of stem cell therapy is if you bring these cells to injured parts of the body, they'll start reproducing and repair that injury.
The great problem at the very start is that researchers need human embryos to do this work, and many people believe these embryos -- which contain about 100 cells and have not yet attached themselves to the walls of a woman's uterus -- are nevertheless human life.
Because of that, President Bush six years ago said that federal funds could only be used to do research on the stem cell lines established at that time. There are about 10 of those lines, Grabel said, and researchers need more.
"We need embryos," she said.
To override the limits, some states have begun funding their own research into stem cells. Connecticut will spend $10 million per year for 10 years on this work, and Grabel has received nearly $1 million of this grant money.
Grabel said private companies also fund the research, but some of them have walked away.
"There isn't a lot of money or a lot of eggs available. Because things aren't happening more quickly, some private companies are closing down," Grabel said.
Ongoing research is complicated. Grabel said in one project at Wesleyan, she and her colleagues injected a solution into mice that causes epilepsy, causing the death of some brain neurons.
They then injected neural stem cells -- stem cells that are in the process of producing neurons -- into the mice to see if they'd migrate to the damaged areas and repair them. Instead, they headed to another section of the brain that is responsible for producing new neurons.
"I think they wanted to go where the signals for new growth are," Grabel said. Knowing that may help researchers manipulate those signals -- and stem cells -- in the future.
Grabel said when mice without epilepsy damage got the stem cells, about 80 percent developed tumors. Many of the tumors contained undifferentiated stem cells -- cells that could grow into different body parts -- rather than neural stems cells, which could only grow into neurons.
"That means we screwed up somewhere," Grabel said.
There are many issues -- tumor production, genetic compatibility, generating the right types of cells for transplant, making sure the stem cells aren't contaminated -- that scientists must face in this research.
While they get resolved, the moral, ethical and political winds continue to blow.
Grabel said despite great hopes, two other forms of stem cells -- adult stem cells and umbilical stem cells -- don't offer the same potential as embryos.
But she also acknowledged great potential for using stem cells to treat any number of diseases, including Type 1 diabetes, multiple sclerosis and Alzheimer's. There has already been definite progress in treating Parkinson's disease and spinal cord injuries in animal models using stem cells.
"But even for them, we're talking about being years and years away from treating humans," she said. "For things like epilepsy, it's even further away."
USA Direct Line:
Don Margolis, Chairman
This Newsletter is for
educational purposes only and not to be taken as medical advice.